HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Eugene KW Sim Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sim, E. K. Articles by Haider, H. K. Search for Related Content PubMed PubMed Citation Articles by Sim, E. K. Articles by Haider, H. K. Related Collections Cardiac - other

New Strategy for Cardiac Repair: Genetically Modified Skeletal Myoblasts

Singapore

The first 20% of the full text of this article appears below.

Skeletal myoblast (SkM) transplantation has been extensively investigated as a potential treatment modality in cardiovascular therapeutics, and the functional benefits of this procedure have been validated in animal models and clinical studies.¹ Preclinical studies have well demonstrated that SkM is a safe and efficient cell type for cardiac repair. It improves systolic and diastolic function, increases myocardial wall thickness, and delimits the ventricular remodeling process. Skeletal myoblasts are as effective as neonatal cardiomyocytes and bone marrow-derived stem cells for cardiac repair.^2–4 Since Menasche and colleagues⁵ reported the first patient to receive autologous SkM transplantation as an adjunct to coronary artery bypass grafting, more than 200 patients have undergone SkM transplantation. Except for transient ventricular tachycardia or arrhythmia observed in some patients, SkM transplantation has been well tolerated in general, and has not been associated with adverse effects. In most patients, there was improvement in New York Heart Association functional class, increased . . . [Full Text of this Article]